Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPACT
NCT03152058Phase 2Recruiting
- Start
- May 2017
- Primary completion
- Dec 2027
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of certolizumab pegol in antiphospholipid syndrome (APS) and pregnancy complications. Primary endpoint: Fetal death and/or preterm delivery (<34 weeks) due to PE or PI. Started May 2017; status: recruiting.
02
Drugs
certolizumab pegol
03
Conditions
antiphospholipid syndrome (APS)pregnancy complications
Beyond the preview
Go deeper on NCT03152058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03152058.